CDXS

Codexis, Inc. [CDXS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CDXS Stock Summary

Top 10 Correlated ETFs

CDXS


Top 10 Correlated Stocks

CDXS


In the News

10:39 28 Mar 2024 CDXS

Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript

Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript

07:51 28 Mar 2024 CDXS

Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates

Codexis (CDXS) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to loss of $0.19 per share a year ago.

08:56 28 Mar 2024 CDXS

WIX Set to Report Q4 Earnings: Here's What You Should Know

WIX Q4 performance is likely to have benefited from an uptake of new products and improvement in the user base.

04:05 28 Mar 2024 CDXS

Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28

REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth quarter and fiscal year 2023 on Wednesday, February 28, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update.

02:46 28 Mar 2024 CDXS

3 Synthetic Biology Stocks Likely to Mint New Millionaires

Synthetic biology refers to using engineered organisms to produce products for multiple industries. Specifically, the pharmaceutical, biotechnology, and agriculture sectors are set to benefit most from synthetic biology.

09:32 28 Mar 2024 CDXS

Codexis, Inc. (CDXS) Q3 2023 Earnings Call Transcript

Codexis, Inc. (CDXS) Q3 2023 Earnings Call Transcript

03:35 28 Mar 2024 CDXS

Codexis to Present Update on ECO Synthesis™ Platform at TIDES Europe

REDWOOD CITY, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced a presentation highlighting the role of an enzymatic approach to support RNA-based therapeutics manufacturing at the TIDES Europe annual meeting taking place in Amsterdam, Netherlands and virtually October 30-November 1, 2023.

04:05 28 Mar 2024 CDXS

Codexis to Report Third Quarter 2023 Financial Results on November 2

REDWOOD CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the third quarter of 2023 on Thursday, November 2, 2023, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update.

02:11 28 Mar 2024 CDXS

Checking Out Codexis

Codexis, Inc. is undergoing a significant restructuring to reduce costs, refocus its developmental efforts and streamline its organization. The company's ECO platform to provide enzymes for RNA therapeutics shows some potential, but the company's cash burn rate remains concerning. Insider purchases and consolidation of operations may indicate a turnaround, but previous insider selling this year raises concerns about management's commitment.

03:02 28 Mar 2024 CDXS

The Next Nvidia: 3 AI Stocks That Could Break New Records

With artificial intelligence protocols requiring a ridiculous amount of computing capacity, the demand surge for graphics processing units (GPUs) naturally boosted Nvidia (NASDAQ: NVDA ) but it also leaves the million-dollar question: what investment will be the next Nvidia? To be sure, no one's questioning the long-term viability of NVDA.

CDXS Financial details

Company Rating
Neutral
Market Cap
242.55M
Income
-76.24M
Revenue
70.14M
Book val./share
1.25
Cash/share
0.94
Dividend
-
Dividend %
-
Employees
174
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-2.3
Forward P/E
-5.29
PEG
-0.2
P/S
2.55
P/B
2.05
P/C
3.83
P/FCF
-8.16
Quick Ratio
2.44
Current Ratio
2.68
Debt / Equity
0.26
LT Debt / Equity
0.14
-
-
EPS (TTM)
-1.11
EPS next Y
-0.68
EPS next Q
-0.18
EPS this Y
119.61%
EPS next Y
-38.44%
EPS next 5Y
-160.36%
EPS last 5Y
39.77%
Revenue last 5Y
0.49%
Revenue Q/Q
186.31%
EPS Q/Q
-80%
-
-
-
-
SMA20
-25%
SMA50
-
SMA100
50%
Inst Own
66.34%
Inst Trans
0.72%
ROA
-53%
ROE
-67%
ROC
-0.68%
Gross Margin
75%
Oper. Margin
-106%
Profit Margin
-110%
Payout
-
Shs Outstand
70.3M
Shs Float
67.25M
-
-
-
-
Target Price
-
52W Range
1.45-4.91
52W High
-10%
52W Low
+259.99%
RSI
55
Rel Volume
0.09
Avg Volume
651.74K
Volume
60K
Perf Week
3.15%
Perf Month
11.11%
Perf Quarter
76.47%
Perf Half Y
139.99%
-
-
-
-
Beta
2.044
-
-
Volatility
0.05%, 0.43%
Prev Close
2.56%
Price
3.5999
Change
4.04%

CDXS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
1.211.161.622.121.03
Net income per share
-0.21-0.4-0.33-0.51-1.12
Operating cash flow per share
-0.22-0.28-0.220.17-0.77
Free cash flow per share
-0.29-0.34-0.440.05-0.84
Cash per share
1.62.531.811.740.96
Book value per share
1.872.872.552.221.27
Tangible book value per share
1.812.812.52.171.24
Share holders equity per share
1.872.872.552.221.27
Interest debt per share
0.460.420.740.690.33
Market cap
903.83M1.3B2.02B304.5M207.8M
Enterprise value
839.45M1.17B1.95B234.16M164.53M
P/E ratio
-75.73-53.97-94.88-9.06-2.73
Price to sales ratio
13.218.7619.272.22.96
POCF ratio
-71.96-78.71-141.5226.99-3.95
PFCF ratio
-55.48-64.11-71.86102.29-3.64
P/B Ratio
8.577.6212.282.12.4
PTB ratio
8.577.6212.282.12.4
EV to sales
12.2616.9718.611.692.35
Enterprise value over EBITDA
-66.89-48.98-85.91-8.2-3.67
EV to operating cash flow
-66.84-71.17-136.6720.75-3.13
EV to free cash flow
-51.53-57.97-69.478.66-2.88
Earnings yield
-0.01-0.02-0.01-0.11-0.37
Free cash flow yield
-0.02-0.02-0.010.01-0.27
Debt to equity
0.250.150.290.30.26
Debt to assets
0.180.110.190.170.16
Net debt to EBITDA
5.135.193.052.460.96
Current ratio
7.427.384.853.322.61
Interest coverage
000-22.010
Income quality
1.050.690.67-0.340.69
Dividend Yield
00000
Payout ratio
-0.24-0.05000
Sales general and administrative to revenue
0.450.50.470.370
Research and developement to revenue
0.490.640.530.580.84
Intangibles to total assets
0.020.010.010.010.02
Capex to operating cash flow
0.30.230.97-0.740.08
Capex to revenue
-0.05-0.05-0.13-0.06-0.06
Capex to depreciation
-0.82-0.82-2.33-0.81-0.45
Stock based compensation to revenue
0.10.110.110.10.14
Graham number
2.985.114.345.065.66
ROIC
-0.08-0.11-0.09-0.14-0.45
Return on tangible assets
-0.08-0.11-0.09-0.14-0.57
Graham Net
1.12.040.990.610.47
Working capital
98.82M159.44M128.52M113.83M57.64M
Tangible asset value
102.28M166.86M161.15M141.56M84.15M
Net current asset value
70.65M132.88M79.9M57.3M43.52M
Invested capital
0.250.150.290.30.26
Average receivables
16.33M24.72M33.47M39.26M30.4M
Average payables
2.84M2.8M2.98M3.12M4.6M
Average inventory
480K667.5K1.06M1.59M2.36M
Days sales outstanding
107.46154.8131.19107.65103.7
Days payables outstanding
61.278.8949.2231.15118.44
Days of inventory on hand
8.6625.619.0619.4753.47
Receivables turnover
3.42.362.783.393.52
Payables turnover
5.964.637.4211.723.08
Inventory turnover
42.1314.2619.1518.746.83
ROE
-0.11-0.14-0.13-0.23-0.88
Capex per share
-0.07-0.06-0.21-0.13-0.06

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.470.20.320.130.38
Net income per share
-0.19-0.34-0.17-0.5-0.1
Operating cash flow per share
0.08-0.14-0.24-0.23-0.16
Free cash flow per share
0.08-0.18-0.26-0.24-0.15
Cash per share
1.751.561.361.070.94
Book value per share
2.231.911.841.321.25
Tangible book value per share
2.181.861.791.281.21
Share holders equity per share
2.231.911.841.321.25
Interest debt per share
0.680.630.610.290.32
Market cap
303.07M272.95M189.2M131.29M211.98M
Enterprise value
232.72M212.46M138.12M76.69M168.7M
P/E ratio
-6.01-3.02-4.1-0.94-7.37
Price to sales ratio
9.9821.038.8714.157.98
POCF ratio
61.64-29.63-11.76-8.05-19.21
PFCF ratio
61.23-23.23-10.71-7.73-19.89
P/B Ratio
2.092.171.521.432.45
PTB ratio
2.092.171.521.432.45
EV to sales
7.6616.376.488.276.35
Enterprise value over EBITDA
-33.64-9.03-14.19-13.274.81
EV to operating cash flow
47.33-23.06-8.59-4.7-15.29
EV to free cash flow
47.01-18.08-7.82-4.52-15.83
Earnings yield
-0.04-0.08-0.06-0.27-0.03
Free cash flow yield
0.02-0.04-0.09-0.13-0.05
Debt to equity
0.30.340.330.220.26
Debt to assets
0.170.190.20.130.16
Net debt to EBITDA
10.172.575.259.39-19.19
Current ratio
3.323.393.362.682.61
Interest coverage
-12.2522.24000
Income quality
-0.390.411.40.471.53
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.40000
Research and developement to revenue
0.651.280.811.470.42
Intangibles to total assets
0.010.010.020.020.02
Capex to operating cash flow
0.010.280.10.04-0.03
Capex to revenue
0-0.2-0.07-0.070.01
Capex to depreciation
0.01-0.94-0.58-0.270.19
Stock based compensation to revenue
0.10.220.130.250.08
Graham number
3.123.842.653.861.7
ROIC
-0.04-0.11-0.06-0.240
Return on tangible assets
-0.05-0.11-0.06-0.23-0.05
Graham Net
0.620.410.40.390.46
Working capital
113.83M91.64M84.31M64.6M57.64M
Tangible asset value
141.56M122.78M120.89M89.04M84.15M
Net current asset value
57.3M37.9M37.41M40.07M43.52M
Invested capital
0.30.340.330.220.26
Average receivables
35.32M30.45M20.81M20.35M19.51M
Average payables
2.93M3.87M4.27M3.57M4.52M
Average inventory
1.83M2.01M2.02M2.18M2.5M
Days sales outstanding
121.11138.7791.22185.2367.52
Days payables outstanding
34.5589.46114.47123.98131.25
Days of inventory on hand
21.639.7358.1192.2459.26
Receivables turnover
0.740.650.990.491.33
Payables turnover
2.611.010.790.730.69
Inventory turnover
4.172.271.550.981.52
ROE
-0.09-0.18-0.09-0.38-0.08
Capex per share
0-0.04-0.02-0.010.01

CDXS Frequently Asked Questions

What is Codexis, Inc. stock symbol ?

Codexis, Inc. is a US stock , located in Redwood city of Ca and trading under the symbol CDXS

What is Codexis, Inc. stock quote today ?

Codexis, Inc. stock price is $3.5999 today.

Is Codexis, Inc. stock public?

Yes, Codexis, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap